Startseite Kongressberichte & Archiv ESMO World Congress on Gastrointestinal Cancer Session XVI: Hepatocellular Cancer - Presentation of Selected Abstracts

Session XVI: Hepatocellular Cancer - Presentation of Selected Abstracts

O-021: Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)
Tim Meyer, et al.

The conclusion from authors abstract:

Ramucirumab improved OS and PFS for patients with advanced HCC and a baseline AFP ≥400 ng/mL, irrespective of prior TACE treatment. A consistent manageable safety profile was also observed irrespective of prior TACE.



O-022: Outcomes based on Albumin‐Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Rebecca Miksad, et al.

The conclusion from authors abstract:

Patients treated with cabozantinib had longer PFS and OS compared to patients receiving placebo, regardless of ALBI grade. Outcomes were generally better in patients with ALBI grade 1 versus 2.

 

O-027: Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240
Richard Finn, et al.

The conclusion from authors abstract:

Pembro reduced the risk of death by 22% and improved PFS vs Pbo in pts with advanced HCC, but significance did not meet prespecified statistical criteria. ORR for Pembro was consistent with that of KEYNOTE-224. New anticancer therapy in the Pbo arm likely impacted OS. The safety profile was comparable to that established for Pembro monotherapy. The results are consistent with those of KEYNOTE-224, further supporting second line therapy with Pembro in HCC pts.